Merck setback

A setback yesterday for Merck, as a Food and Drug Administration advisory panel overwhelmingly recommended that the body not approve Arcoxia, a pain pill...

A setback yesterday for Merck, as a Food and Drug Administration advisory panel overwhelmingly recommended that the body not approve Arcoxia, a pain pill related to the ill-fated Vioxx. The FDA is expected to weigh in on April 27, and usually follows the recommendations of the advisory panel. GCI Group assists Merck with the drug.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.